The weight loss drug Wegovy was also discounted
Novo Nordisk (NOVOb.CO), said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive dynamic of the U.S. obesity drug market.
The move comes just over a week after rival Eli Lilly (LLY.N), cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online through its direct-to-consumer website.
Novo said its discounted Wegovy would be available in pens of all dosage strengths to uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines through its NovoCare Pharmacy program.
